|
1）Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014; 21: 221-4
|
|
|
|
2）Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012; 16: 903-20
|
|
|
|
|
3）Benson MD, James S, Scott K, et al. Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int. 2008; 74: 218-22
|
|
|
|
|
|
4）Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012; 82: 226-34
|
|
|
|
|
|
5）Teng J, Turbat-Herrera EA, Herrera GA. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes. Kidney Int. 2014; 86: 738-46
|
|
|
|
|
|
6）Owen-Casey MP, Sim R, Cook HT, et al. Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. J Clin Pathol. 2014; 67: 661-6
|
|
|
|
|
|
7）Sun W, Sun J, Zou L, et al. The successful diagnosis and typing of systemic amyloidosis using a microwave-assisted filter-aided fast sample preparation method and LC/MS/MS analysis. PLoS One. 2015; 10: e0127180
|
|
|
|
|
|
8）Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014; 99: 1239-47
|
|
|
|
|
|
9）Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006; 119: 355 e315-24
|
|
|
|
|
|
10）Wall JS, Kennel SJ, Paulus M, et al. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med. 2006; 47: 2016-24
|
|
|
|
|
|
11）Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010; 116: 2241-4
|
|
|
|
|
|
12）Mekinian A, Jaccard A, Soussan M, et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid. 2012; 19: 94-8
|
|
|
|
|
|
13）Glaudemans AW, Slart RH, Noordzij W, et al. Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging. 2013; 40: 1095-101
|
|
|
|
|
|
14）Hellstrom-Lindahl E, Westermark P, Antoni G, et al. In vitro binding of [(3)H]PIB to human amyloid deposits of different types. Amyloid. 2014; 21: 21-7
|
|
|
|
|
|
15）Takahashi N, Hasegawa K, Yamaguchi I, et al. Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro. Biochim Biophys Acta. 2002; 1601: 110-20
|
|
|
|
|
|
16）del Pozo-Yauner L, Wall JS, Gonzalez Andrade M, et al. The N-terminal strand modulates immunoglobulin light chain fibrillogenesis. Biochem Biophys Res Commun. 2014; 443: 495-9
|
|
|
|
|
|
17）Nokwe CN, Zacharias M, Yagi H, et al. A residue-specific shift in stability and amyloidogenicity of antibody variable domains. J Biol Chem. 2014; 289: 26829-46
|
|
|
|
|
|
18）Gonzalez-Andrade M, Becerril-Lujan B, Sanchez-Lopez R, et al. Mutational and genetic determinants of lambda6 light chain amyloidogenesis. FEBS J. 2013; 280: 6173-83
|
|
|
|
|
|
19）Kobayashi Y, Tsutsumi H, Abe T, et al. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain. Biochemistry. 2014; 53: 5162-73
|
|
|
|
|
|
20）Feige MJ, Groscurth S, Marcinowski M, et al. The structure of a folding intermediate provides insight into differences in immunoglobulin amyloidogenicity. Proc Natl Acad Sci U S A. 2008; 105: 13373-8
|
|
|
|
|
|
21）Yamamoto K, Yagi H, Lee YH, et al. The amyloid fibrils of the constant domain of immunoglobulin light chain. FEBS Lett. 2010; 584: 3348-53
|
|
|
|
|
|
22）Yamaguchi I, Suda H, Tsuzuike N, et al. Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro. Kidney Int. 2003; 64: 1080-8
|
|
|
|
|
|
23）Yamamoto S, Yamaguchi I, Hasegawa K, et al. Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol. 2004; 15: 126-33
|
|
|
|
|
|
24）Ren R, Hong Z, Gong H, et al. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J Biol Chem. 2010; 285: 37672-82
|
|
|
|
|
|
25）Martin DJ, Ramirez-Alvarado M. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys Chem. 2011; 158: 81-9
|
|
|
|
|
|
26）Brumshtein B, Esswein SR, Landau M, et al. Formation of amyloid fibers by monomeric light chain variable domains. J Biol Chem. 2014; 289: 27513-25
|
|
|
|
|
|
27）Kluve-Beckerman B, Liepnieks JJ, Wang L, et al. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol. 1999; 155: 123-33
|
|
|
|
|
|
28）Sasatomi Y, Kiyoshi Y, Uesugi N, et al. Prognosis of renal amyloidosis: a clinicopathological study using cluster analysis. Nephron. 2001; 87: 42-9
|
|
|
|
|
|
29）Nasr SH, Dogan A, Larsen CP. Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol. 2015 Apr 14. [Epub ahead of print]
|
|
|
|
|
|
30）Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014; 86: 370-7
|
|
|
|
|
|
31）Larsen C. Leukocyte chemotactic factor 2 amyloidosis can be reliably diagnosed by immunohistochemical staining. Hum Pathol. 2014; 45: 2179
|
|
|
|
|
|
32）Paueksakon P, Fogo AB, Sethi S. Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. Hum Pathol. 2014; 45: 1445-50
|
|
|
|
|
|
33）Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001; 104: 1594-7
|
|
|
|
|
|
34）Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004; 94: 1008-10
|
|
|
|
|
|
35）Migrino RQ, Hari P, Gutterman DD, et al. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol. 2010; 145: 67-8
|
|
|
|
|
|
36）Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010; 107: 4188-93
|
|
|
|
|
|
37）Migrino RQ, Truran S, Gutterman DD, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011; 301: H2305-12
|
|
|
|
|
|
38）Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2014; 6: 1493-507
|
|
|
|
|
|
39）Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010; 468: 93-7
|
|
|
|
|
|
40）Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One. 2012; 7: e52686
|
|
|
|
|
|
41）Hovey BM, Ward JE, Soo Hoo P, et al. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 2011; 18: 1150-6
|
|
|
|
|